Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia

Critical Care Medicine

Volumn 40, Issue 8, 2012, Pages 2310-2314

  Wilson, Bryan Z ^a   Anzueto, Antonio ^a,c   Restrepo, Marcos I ^a,c   Pugh, Mary Jo V ^a,d   Mortensen, Eric M ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Division of Hospital Medicine   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERTAPENEM; ERYTHROMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MACROLIDES; MALE; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; PROPENSITY SCORE; RETROSPECTIVE STUDIES;

EID: 84864278373     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825151a8     Document Type: Article

References (37)

1. Heron M, Hoyert DL, Murphy SL, et al: Deaths: Final data for 2006. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System 2009; 57:1-134.
2. Bartlett JG, Dowell SF, Mandell LA, et al: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-382. (Pubitemid 32289567)
3. British Thoracic Society Standards of Care Committee: BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001. 56(Suppl 4):IV1-64.
4. Gialdroni Grassi G, Bianchi L: Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy. Monaldi Arch Chest Dis 1995; 50:21-27.
5. Niederman M, Bass JB, Campbell GD, et al: Guidelines for the initial management of adult with community-acquired pneumnia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148:1418-1426. (Pubitemid 23326049)
6. Niederman MS, Mandell LA, Anzueto A, et al: American Thoracic Society: Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754. (Pubitemid 32578779)
7. Niederman MS: Community-acquired pneumonia: The U.S. perspective. Semin Respir Crit Care Med 2009; 30:179-188.
8. Battleman DS, Callahan M, Thaler HT: Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: Link between quality of care and resource utilization. Arch Intern Med 2002; 162:682-688. (Pubitemid 34226395)
9. Gleason PP, Meehan TP, Fine JM, et al: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-2572.
10. Houck PM, MacLehose RF, Niederman MS, et al: Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western States: 1993, 1995, and 1997. Chest 2001; 119:1420-1426. (Pubitemid 32686024)
11. Martínez JA, Horcajada JP, Almela M, et al: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-395. (Pubitemid 36241302)
12. Stahl JE, Barza M, DesJardin J, et al: Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-2580.
13. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842. (Pubitemid 32762726)
14. Mortensen EM, Restrepo MI, Anzueto A, et al: The association of empiric antimicrobial therapy with a beta-lactam plus fluoroquinolone and mortality for patients with communityacquired pneumonia. Crit Care 2006; 10:R8.
15. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-383. (Pubitemid 17055592)
16. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-1251. (Pubitemid 24361532)
17. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-619.
18. Mortensen EM, Coley CM, Singer DE, et al: Causes of death for patients with communityacquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162:1059-1064. (Pubitemid 34492537)
19. Mortensen EM, Kapoor WN, Chang CC, et al: Assessment of mortality after long-term follow-up of patients with communityacquired pneumonia. Clin Infect Dis 2003; 37:1617-1624. (Pubitemid 37549947)
20. Sohn MW, Arnold N, Maynard C, et al: Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006; 4:2.
21. Dasta JF, McLaughlin TP, Mody SH, et al: Daily cost of an intensive care unit day: The contribution of mechanical ventilation. Crit Care Med 2005; 33:1266-1271. (Pubitemid 40827376)
22. Malone DC, Shaban HM: Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001; 35:1180-1185. (Pubitemid 32959183)
23. Restrepo MI, Mortensen EM, Waterer GW, et al: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-159.
24. Brown RB, Iannini P, Gross P, et al: Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: Analysis of a hospital claims-made database. Chest 2003; 123:1503-1511. (Pubitemid 36549769)
25. Burgess DS, Lewis JS 2nd: Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22:872-878. (Pubitemid 30625919)
26. Culic O, Erakovic V, Cepelak I, et al: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450:277-289.
27. Culic O, Erakovic V, Parnham MJ: Antiinflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-229.
28. Ianaro A, Ialenti A, Maffia P, et al: Antiinflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292:156-163.
29. Labro MT: Anti-inflammatory activity of macrolides: A new therapeutic potential? J Antimicrob Chemother 1998; 41(Suppl B):37-46. (Pubitemid 28152222)
30. Fischer E, Marano MA, Van Zee KJ, et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-1557.
31. van der Poll T, van Deventer SJ, Hack CE, et al: Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79:693-698.
32. Moussa K, Michie HJ, Cree IA, et al: Phagocyte function and cytokine production in community acquired pneumonia. Thorax 1994; 49:107-111. (Pubitemid 24115440)
33. Puren AJ, Feldman C, Savage N, et al: Patterns of cytokine expression in community-acquired pneumonia. Chest 1995; 107:1342-1349.
34. Ortqvist A, Hedlund J, Wretlind B, et al: Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995; 27:457-462.
35. Bauer TT, Montón C, Torres A, et al: Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000; 55:46-52. (Pubitemid 30248778)
36. Niederman MS: Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: Maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42(Suppl 2):S72-S81. (Pubitemid 43054218)
37. Kopterides P, Koletsi PK, Michalopoulos A, et al: Exposure to quinolones is associated with carbapenem resistance among colistinsusceptible Acinetobacter baumannii blood isolates. Int J Antimicrob Agents 2007; 30:409-414. (Pubitemid 47498964)